Jan 25 (Reuters) - The European health regulator's advisory panel issued a negative opinion for PTC Therapeutics' drug to treat Duchenne muscular dystrophy (DMD), an inherited progressive muscle-wasting disorder, the company said on Thursday. (Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.14 USD | -2.04% | -8.84% | +12.99% |
04-30 | North American Morning Briefing : More Earnings -2- | DJ |
04-29 | Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.99% | 2.39B | |
+2.93% | 108B | |
-3.70% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B | |
+329.39% | 8.81B |
- Stock Market
- Equities
- PTCT Stock
- News PTC Therapeutics, Inc.
- PTC Therapeutics' muscle disorder drug fails to secure EU regulator backing